

Programme

Wednesday 05/07/2023

07:30 **Registration**

08:45 **Opening Ceremony**

Mrs Mady DORCHIES-BRILLON (RÉGION HAUTS-DE-FRANCE, LILLE, France)
Prof. Franck DUMEIGNIL (UNIVERSITY OF LILLE, Lille, France)
Dr Jean-Yves ORTHOLAND (EDELIS, Lyon, France)
Prof. Nicolas WILLAND (INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)

Session 1: Hit Finding

Session chair

Dr Priscille BRODIN
(INSERM - UNIVERSITÉ DE LILLE, Lille, France)

09:15 **PL01 - Fragment-based Design of Methionine Adenosyl Transferase (MAT2a) Inhibitors with Anti-tumour Effect**

Dr Marianne SCHIMPL
(ASTRAZENECA, Cambridge, United Kingdom)

09:50 **PL02 - Identification of CDK8 Inhibitors as Inducers of Tendon Cell Differentiation through Phenotypic Screening and Chemoproteomics**

Dr Jean-Baptiste LANGLOIS
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

10:25 **Coffee Break sponsored by Merck, Networking & Exhibition**

Session 2: New Avenues in Drug Discovery Chemistry

Session chair

Dr Jean QUANCARD
(NOVARTIS, Basel, Switzerland)

10:55 **PL03 - Discovery of Novel Microbiome-Sparing Antibiotics with Activity Against Gram-Negative Pathogens**

Prof. Paul J. HERGENROTHER
(UNIVERSITY OF ILLINOIS, Urbana, United States)

11:30 **PL04 - Electrochemistry in High-Throughput**

Dr Nessa CARSON
(ASTRAZENECA, Macclesfield, United Kingdom)

12:05 **OC01 - Experiences from CETSA Screens for Hit Discovery versus Challenging Targets**

Dr Alice LANNE
(ASTRAZENECA, Macclesfield, United Kingdom)

12:25 **Lunch, Networking & Exhibition**

13:15 **Poster Session I (posters with odd numbers), Networking & Exhibition**

Programme

Session 3: New Molecular Landscapes in Drug Discovery

Session chair

Dr Nicolas GEORGE
(AQEMIA, Paris, France)

- 14:45 PL05 - Stabilizing Relevant GPCR Conformations to Discover Therapeutic Antibodies**
Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)
- 15:20 PL06 - LipMate (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral Drugs**
Dr Antonia F. STEPAN
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- 15:55 OC02 - Potential of Chloroalkene as Amide Bond Isostere**
Prof. Tetsuo NARUMI
(SHIZUOKA UNIVERSITY, Hamamatsu, Japan)
- 16:15 OC03 - Scaffold out of the Blue: Azulenes for Medicinal Chemistry**
Dr Jörg KLEY
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)
- 16:35 Coffee Break, Networking & Exhibition**

Session 4: Late-Breaking Topics: First Disclosures of Clinical Candidates and Cases Studies

Session chair

Prof. Benoit DEPRez
(INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)

- 17:05 PL07 - Discovery of GLPG3970, A First-in-class SIK2/SIK3 Inhibitor Evaluated in Clinical Trials for the Treatment of Autoimmune and Inflammatory Diseases**
Dr Christophe PEIXOTO
(GALAPAGOS, Romainville, France)
- 17:40 PL08 - Leucettinib-21, A DYRK1A Inhibitor Drug Candidate Aiming at the Correction of Cognitive Disorders in People with Down Syndrome or Alzheimer's Disease**
Dr Laurent MEIJER
(PERHA PHARMACEUTICALS, Roscoff, France)
- 18:15 PL09 - Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection**
Dr Wei ZHU
(CHINA INNOVATION CENTER OF ROCHE (CICOR), Shanghai, China)
- 18:50 Welcome Reception**
- 20:30 End of the Day**

Thursday 06/07/2023

Session 5: Evotec Prize for Excellence in Molecular Design

Session chairs

Dr Jean-Yves ORTHOLAND (EDELIRIS, Lyon, France)
Dr Christophe BOLDRON (EVOTEC, Toulouse, France)

08:45 PL10 - Modulation of Protein – Protein Interactions by Means of Peptidomimetics

Prof. Steven BALLEET
(VRIJE UNIVERSITEIT BRUSSEL, Brussels, Belgium)

09:45 Session 6: Neurodegenerative Diseases

Session chair

Prof. Patricia MELNYK
(INSERM - UNIVERSITÉ DE LILLE, Lille, France)

09:45 PL11 - Structural Biology Supporting Medicinal Chemistry of Purine Receptors

Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

10:20 OC04 - Unravelling the Potential of the Type 2 Lysophosphatidic Acid Receptor (LPA2) for Central Nervous System Pathologies

Prof. Silvia ORTEGA GUTIERREZ
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)

10:40 Coffee Break, Networking & Exhibition

Session 7: Covalent Inhibitors in Drug Discovery

Session chair

Dr Didier ROCHE
(EDELIRIS, Lyon, France)

11:10 PL12 - Development of SARS Coronavirus 3CL Protease Inhibitors with an Electrophilic aryl-ketone Warhead

Prof. Yoshio HAYASHI
(TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, Tokyo, Japan)

11:45 PL13 - Inhibitors of the Mitochondrial Sirtuins 3 and 5

Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

12:20 Lunch, Networking & Exhibition

**12:35 SCHRÖDINGER WORKSHOP (optional but subject to prior registration)
Augmenting Medicinal Chemistry with Digital Chemistry: a CDK2 Inhibitor Design Challenge**

13:15 Poster Session II (posters with even), Networking & Exhibition

Programme

Session 8: Next Generation of Anti-infective Agents

Session chair

Dr Baptiste VILLEMAGNE
(INSERM - UNIVERSITÉ DE LILLE, Lille, France)

- 14:45 PL14 - BacPROTACs Mediate Targeted Protein Degradation in Bacteria**
Prof. Francesca Ester MORREALE
(THE FRANCIS CRICK INSTITUTE, London, United Kingdom)
- 15:20 OC05 - Tackling LysS, a New Target for Tuberculosis**
Dr Laura A.T. CLEGHORN
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)
- 15:40 OC06 - Historical Evolution and Lessons Learned from an RSV Non Nucleosides Polymerase Inhibitor Program**
Dr Sandrine GROSSE
(JANSSEN, Beerse, Belgium)
- 16:00 Coffee Break, Networking & Exhibition**
- 16:30 PL15 - Metallo-Enzymes - From Functions to Drugs**
Prof. Christopher J. SCHOFIELD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Session 9: Small Molecules for Immunooncology or Autoimmunity

Session chair

Prof. Rebecca DEPREZ-POULAIN
(INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)

- 17:05 PL16 - Discovery of the Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist with Therapeutic Potential in Autoimmune Diseases**
Dr Eva CAROFF
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland)
- 17:40 OC07 - Discovery of an Oral, Rule-of-5 Compliant, IL-17A Protein-Protein Interaction Modulator (IL-17A PPI) for the Treatment of Psoriasis and other Inflammatory Diseases.**
Dr Mark D. ANDREWS
(LEO PHARMA, Ballerup, Denmark)
- 18:00 OC08 - Small-Molecule Inhibitor Targeting PD-1/PD-L1 Interaction Restores T-Cell Function**
Prof. Helena FLORINDO
(IMED - UNIVERSITY OF LISBON, Lisbon, Portugal)
- 18:20 End of the Day**
- 20:00 Symposium Banquet (subject to prior registration)**

Friday 07/07/2023

Session 10: Beyond PROTACS

Session chair

Dr Guillaume LACONDE
(OXELTIS, Montpellier, France)

08:45 PL17 - Bifunctional Molecules for Exploring and Treating Human Disease

Prof. David SPIEGEL
(YALE UNIVERSITY, New Haven, United States)

09:20 PL18 - A Tricycle Journey to in vivo Degraders of the Oncogenic Transcription Factor BCL6

Prof. Swen HOELDER
(THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom)

09:55 PL19 - Expansion of the Druggable Genome through Rational Approaches to Molecular Glue Discovery

Dr Rohan BECKWITH
(NEOMORPH INC., San Diego, United States)

10:30 Coffee Break, Networking & Exhibition

Session 11: Galapagos Award For Drug Discovery Chemistry

Session chair

Dr Jean-Yves ORTHOLAND (EDELIRIS, Lyon, France)
Dr Sandrine VENDEVILLE (GALAPAGOS, Beerse, Belgium)

11:00 PL20 - Peptide, A Manifesto

Prof. Philippe KAROYAN
(SORBONNE UNIVERSITÉ, VILLEBON SUR YVETTE, France)

12:00 Closing Ceremony

12:30 End of the Symposium